Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

Trastuzumab deruxtecan (T‐DXd) is a HER2‐targeting antibody‐drug conjugate composed of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor payload. T‐DXd has been approved for HER2‐positive metastatic breast cancer and for HER2‐positive metastatic gastric cancer. The app...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Ophelia, Iwata, Hiroji, Lin, Chia‐Chi, Tamura, Kenji, Watanabe, Junichiro, Wada, Russ, Kastrissios, Helen, AbuTarif, Malaz, Garimella, Tushar, Lee, Caleb, Zhang, Lin, Shahidi, Javad, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518417/
https://www.ncbi.nlm.nih.gov/pubmed/33999422
http://dx.doi.org/10.1002/cpt.2291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518417/
https://www.ncbi.nlm.nih.gov/pubmed/33999422
http://dx.doi.org/10.1002/cpt.2291

Ejemplares similares